(Q34752154)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Karel Pavelka

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Martina Skácelová

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Karel Hejduk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Andrea Smržová

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

2 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

1451-1458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

CTLA-4 is a second receptor for the B cell activation antigen B7

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Short form 36 (SF36) health survey questionnaire: normative data for adults of working age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Abatacept in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2303-6

RA in 2011: Advances in diagnosis, treatment and definition of remission

21 January 2018

1 reference

12 December 2020

Adverse effects of biologics: a network meta-analysis and Cochrane overview

1 reference

12 December 2020

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

The evaluation of drugs: whose responsibility? CIOMS Round Table Conference, October 1968

1 reference

12 December 2020

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

10.1007/S10067-013-2303-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728498%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference